Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab Plus Imfinzi in Stage III NSCLC

Arcus Biosciences announced a collaboration with AstraZeneca to evaluate domvanalimab (AB154), Arcus’s investigational anti-TIGIT antibody, in combination with AZ's Imfinzi (durvalumab) in a registrational Phase III clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Under the terms of the agreement, each company will retain existing rights to their respective molecules and any future commercial economics. AstraZeneca will conduct the trial, and each company will supply its respective anti-cancer agent to support the trial. Pursuant to the terms of the agreement, the parties will share costs for the trial. Consistent with the terms of the recently completed Arcus-Gilead partnership, Gilead maintains an option to co-develop and co-commercialize domvanalimab. If Gilead exercises its option to domvanalimab, the trial from this AstraZeneca collaboration is expected to form part of the Arcus and Gilead joint development program and Arcus’s portion of the trial costs would be shared with Gilead.